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Editorial on the Research Topic
Cancer Ecosystems
Oncology research pioneers such as Stephen Paget focused on how cancer cells favor particular
environments (1) and Judah Folkman on how nutrients are provided to these harsh environments
(2). The tumors consist of a heterogeneous population of cancer cells and a stroma with different
cell types that define a specific microenvironment and form a tumoral ecosystem. The evolution of
the tumors depends on the interactions of the cancer cells with their tumor microenvironment
(TME), determining the progression, eradication, or tumor metastasis. A coral ecosystem is
similar to tumors in that it is highly complex and energetically productive (3, 4) (Table 1).
A tropical reef-building coral holobiont is composed of the coral metazoan host (the polyp),
its endosymbiotic photosynthetic dinoflagellates (Symbiodiniaceae) and other microorganisms,
including protozoans, fungi, bacteria, and archaea (5). Despite their complexity and very high
productivity, corals commonly thrive in nutrient-poor environments (14), which are similar to
what is observed in tumors. The contradiction of high coral productivity and limited nutrient
availability has been named as the “Darwin Paradox,” in reference to its first discoverer (19). This
paradox can be explained by the high uptake and efficient recycling of nutrients by coral reef
organisms. A similar paradox has been observed in tumors since it is unclear how this complex
ecosystem thrives in such nutrient deprived conditions (4).
Scientists have debated how the extremely high productivity and diversity of coral reefs can
thrive while living in such an oligotrophic environment, equivalent to a marine desert (13, 20). The
answer relies on coral mutualistic relationships that allow the retention of resources and avoid their
drift away in ocean currents. Sponges have been found to be the basis of this recycling of nutrients
and energy back into the ecosystem (13). The largest resource produced on reefs are dissolved in
organic matter (DOM), and sponges allow DOM to be transferred to higher trophic levels (13). In
tumors, Otto Warburg focused on the idea that the key organic matter is glucose. He postulated
that tumor cells maintain high glycolytic rates even with adequate oxygen supply, although he did
not address how glucose becomes available to cancer cells (21). Compared to differentiated cells,
many tumor cells have an altered energy metabolism. In particular, a change in metabolism based
on respiration to one which is predominantly glycolytic (22, 23). Many glycolytic-related genes are
systematically overexpressed in different types of cancer cells, have diagnostic utility, and may help
predict therapeutic response (24). These data situate the glycolytic phenotype as a distinctive sign
of tumor cells (22, 23, 25), providing advantages for proliferation.
Phosphofructokinase 1 (PFK1) and monocarboxylate transporter 4 (MCT4) are
rate limiting steps in glycolysis (26). In this e-book collection, the role of one of the
main glycolytic regulators, fructose 2,6-bisphosphate (Fru-2,6-P2), in cancer cells is
reviewed by Bartrons et al. Fru-2,6-P2 allosterically induces PFK1 activity. TP53 Induced
Glycolysis and Apoptosis Regulator (TIGAR) also regulates glycolysis via Fru-2,6-P2 and
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TABLE 1 | Examples of similarities between Tumor and Coral Reef Ecosystems.
Tumor Coral reef
Highly complex ecosystems with
high nutrient utilization rates (4)
Highly complex ecosystems with high





Nitrogen and Phosphorus deprivation
(5–7)
Compromised water flow (8)
Metabolic coupling:
Between cancer and stromal
cells (9)
Between cancer cells (10)
Between cancer cell organelles
(Herst et al.)
Metabolic coupling:
Between coral and fish (11, 12)







bacteria in metabolic coupling (15)








drives metabolic symbiosis between cancer cells and cancer-
associated fibroblasts (27). Another key regulator of glycolysis:
monocarboxylate transporter 4 (MCT4) is also studied by Bisetto
et al. and found to induce tumor aggressiveness. MCT4 is
the main exporter of lactate from cells, a marker of glycolysis
and is regulated by HIF-1α. Conversely, MCT1 is the main
importer of lactate into cells, a marker of mitochondrial oxidative
phosphorylation and is regulated by c-MYC (4). Most complex
ecosystems such as coral reefs and tumors have heterogeneous
metabolic activity. Only some cells have high activity of a
particular metabolic pathway. As an example, MCT1 is highly
expressed in cancer cells while MCT1 expression is low or absent
in tumor-associated macrophages (28).
Cancer cells and corals do not exist in isolation. In fact,
all living entities host diverse symbionts that contribute to
their associated functions. Most studies on the metabolism of
cancer cells have focused on the investigation of a single type
of intra-tumoral cell, although recent studies have described a
more complex scene, where the tumor ecosystem via metabolic
symbiosis plays a critical role in cancer progression (9, 10, 29).
Similar metabolic interactions to those observed in tumors occur
in corals. The “coral probiotic hypothesis” states that corals have
a dynamic relationship with their symbiotic microorganisms. By
altering the population of symbionts, the coral host adapts to a
changing environment. This adjustment of a time span of days
to weeks is faster than if it were via mutation and selection
that would take many years (30). In sum, it is the combined
holobiont that exerts the unit of natural selection as opposed to
its individual members and it has been named the hologenome
theory of evolution (31).
Cancer cells have a great capacity to adapt to changes in
the conditions of their TME, developing survival strategies
(Leverson and Cojocari). Similar plasticity has been observed
in coral reefs (17). The tumor and stromal cells establish
a powerful relationship that determines the initiation and
progression of the disease, as well as the patient’s prognosis
(32). Physiologically, the stroma is a physical barrier against
tumorigenesis; however, cancer cells elicit changes to convert
the adjacent TME into a pathological entity, favoring nutrient
exchange, migration of stromal cells, matrix remodeling, and
expansion of the vasculature. In addition to malignant cells, the
TME contains stromal cells that have been implicated in tumor
promotion, such as endothelial cells of the blood and lymphatic
circulatory system, pericytes, fibroblasts, and various bone
marrow derived cells, including macrophages, neutrophils, mast
cells, myeloid cell-derived suppressor cells, and mesenchymal
stem cells, and sometimes even adipocytes (33). The Coral–
Symbiodiniaceae relationship depends on nutrient interactions
and metabolism between the coral host and the microbial
symbionts in response to environmental conditions (34), sharing
features with intercellular relationships in tumors. In fact, species
richness is a key driver of community biomass production and
ecosystem function across a range of ecosystems (35).
Fibroblasts in the TME can be activated. Here they are
referred to as cancer-associated fibroblasts (CAFs), and they
can be recruited to the tumor by different cytokines and
growth factors released by cancer and infiltrated cells. Activation
into CAFs is accomplished through genetic modifications and
altered activation of different signaling pathways, such as NFκB,
IL-6/STAT3, FGF-2/FGFR1, and TGF-β/SMAD (Herst et al.).
Recent research, reviewed by Herst et al., shows that stromal
cells have the ability to transfer mitochondria to tumor cells
deficient in respiration, thus restoring mitochondrial respiratory
capacity. Alterations in nuclear and mitochondrial DNA can
affect mitochondrial respiration, forcing the cells to search for
anaerobic pathways for obtaining energy. These cells with a
predominantly glycolytic metabolism tend to have rapid growth,
are resistant to hypoxia and can produce metastasis. In contrast,
cells lackingmitochondrial DNA cannot form tumors unless they
incorporate mitochondrial DNA from neighboring cells. These
data suggest that mitochondrial exchange between cells could
be used as an additional target in the treatment of cancer. In
addition, cancer cells as well as different stromal cells can modify
their metabolism in response to different signaling pathways,
which can affect the therapeutic response. The resilience of
coral reefs to global warming is also dependent on the crosstalk
between different cells in this ecosystem (36). In this sense,
the NFκB transcription factor, important in regulating cellular
responses, is activated when elevated water temperature or
other environmental perturbations induce the loss of the algal
symbiont Symbiodinium (37) (Table 1).
The crosstalk between cancer cells and macrophages in
the TME is investigated by Li et al., with the aim of
study the intercellular communication in the tumor ecosystem.
Identification of the different mechanisms of transport between
the cells of the TME is essential to understand the mechanisms of
tumor growth and is herein reviewed by Lou et al. These authors
demonstrate that the intercellular exchange of microRNAs,
mitochondria and other components is carried out through
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tunneling nanotubes (TNTs), cytoplasmic extensions based on
actin. This transport through TNTs between malignant and
stromal cells can modify the gene regulation and metabolism of
TME cells, playing a critical role in tumor growth and metastasis,
as well as in resistance to different treatments. Similarly,
species particular trait values, such as fast growth rates and
unique feeding strategies, can strongly affect ecosystem functions,
such as coral reef productivity and nutrient cycling (38, 39).
Alternatively, biodiversity can enhance ecosystem efficiency with
a more complete utilization of resources (40–42). Such synergies
are common in ecosystems like coral reefs, often occurring when
functionally distinctive taxa increase the performance of other
members of the ecosystem (43, 44) (Table 1).
The growth of tumor cells requires the supply of nutrients and
oxygen. Therefore, the angiogenic program driven by TME cells
is one of the first requirements in the tumoral ecosystem (2) and
it is explored by Zuazo-Gaztelu and Casanovas. Angiogenesis, in
addition to providing nutrients and oxygen, also facilitates the
spread of tumor cells. Therefore, the blockade of this process has
been proposed in the treatment of different types of cancer [(2);
Zuazo-Gaztelu and Casanovas]. In this review, special emphasis
is done on the interaction between tumor and stromal cells,
suggesting that the molecular mechanisms of these interactions
may be used for the development of new antiangiogenic agents.
Coral reefs are also subjected to nutrient deprivation on the basis
of changes in water flow (Table 1).
The protection offered by TME to tumor growth can be
diminished by conditions such as chronic inflammation, with
the subsequent release of cytokines and growth factors (45).
In this way, chronic inflammation can trigger a response
in which the proliferative signals induced by stromal cells
are gradually enlarged. Fabregat and Caballero-Díaz review
the role of TGF-β in hepatocarcinogenesis, considering that
when chronic inflammation is established, inflammatory
cells produce mediators, such as TGF-β, responsible for the
activation of quiescent hepatic stellate cells to myofibroblasts
(MFB), which mediate the synthesis of extracellular matrix
proteins and are responsible of fibrogenesis. In parallel, TGF-β
induces also changes in tumor cell characteristics, conferring
migratory properties (Fabregat and Caballero-Díaz), as well
as a glycolytic phenotype (46). TGF-β can also play important
roles in the symbiotic or mutualistic relationships within coral
reefs (Table 1).
Cancer cells near blood vessels grow at a higher rate,
due to the high availability of nutrients and oxygen. Their
energetic needs are supported by glycolysis and mitochondrial
oxidative phosphorylation. In contrast, cells exposed to a
microenvironment where nutrient and oxygen supplies are
reduced, depend more on glycolysis which requires novel
strategies to survive and proliferate. Thus, it is not surprising
that these cells display higher grades of malignancy and chemo-
resistance. Metabolic synergy between cancer and stroma cells
is a driver of cancer aggressiveness and it has been shown
that lactate is an essential metabolic intermediate between TME
cells, fueling the oxidative metabolism of oxygenated tumor
cells. In this way, a tumor symbiosis is produced by which
the glycolytic and oxidative cells exchange metabolic substrates
(4, 10). This metabolic compartmentalization allows for the
exchange of metabolites between stroma and cancer cells, and
this synergy is a result of differential expression of transporters
and isoenzymes (10, 29). The article by Bisetto et al. studies the
role of MCT4, an exporter of lactate, in head and neck squamous
cell carcinoma (HNSCC) aggressiveness. It is demonstrated that
MCT4 is a driver of aggressive cancer, it may be used as a
diagnostic marker and its inhibitors could have therapeutic utility
to prevent invasive HNSCC (Bisetto et al.).
We are beginning to understand the factors and pathways
driving the glycolytic phenotype and metabolic reprogramming
of tumor cells. Many genes are involved in this transformation,
including RAS, TP53, HIF-1, and c-MYC. Although the change to
the glycolytic phenotype is not an indispensable requirement for
malignant transformation, the majority of studies indicate that it
is an important phenomenon associated with survival advantage
for the cells in the TME. In the review by Vaziri-Gohar et al.,
mutant KRAS is analyzed as an important player in the metabolic
reprogramming of the pancreatic ductal adenocarcinoma cells
(PDA). There is growing interest in the therapeutic exploitation
of new metabolic inhibitors and in this review several clinical
trials currently underway in patients with PDA are discussed.
A new and promising strategy for the cancer treatment uses
mitochondria, since they are important in the regulation of
metabolism and apoptosis. Cancer cell mitochondria exhibit
multiple differential features with respect to that of normal cells.
Among them, a stronger mitochondrial membrane potential
that can allow the accumulation of cytotoxic cationic molecules
within the cancer cells. González-Rubio et al. investigate the
selective cytotoxic effect of cationic 10-N-nonyl acridine orange
(NAO) on human lung carcinoma H520 cells. This compound is
able to interfere with mitochondrial function and is a promising
antitumor agent. In a similar way, mitochondrial anti-apoptotic
proteins like BCL-2, BCL-XL, and MCL-1 are overexpressed
in cancer cells (47) and offer a mechanism of survival and
selective advantage in the nutrient deprived environment of
tumors and are therefore attractive drug targets. Leverson and
Cojocari review the literature on the BCL-2-inhibitor Venetoclax,
approved for use in chronic lymphocytic leukemia and now being
studied in a number of other hematologic malignancies. The
results presented suggest that lymphoidmicroenvironments have
a preponderant role in the sensitivity of cancer cells to Venetoclax
(48). Scatena et al. identified new therapeutic targets that are
relatively unique to cancer stem cells (CSCs). CSCs overexpress
regulatory proteins of mitochondrial activity and their inhibition
may represent a potentially new approach to eradicating CSCs.
Different FDA-approved antibiotics, including Doxycycline,
target mitochondria and the results obtained with this drug
clearly show that it can selectively eradicate CSCs in breast cancer
patients in vivo (Scatena et al.). Applying translational research,
a clinical trial performed by Curry et al. used Metformin, an
oral anti-diabetic drug that inhibits mitochondrial complex I, in
patients with head and neck squamous cell carcinoma (HNSCC).
Metformin resulted in an increase in cancer cell apoptosis and
altered the cellular TME with an increased infiltrate of CD8+
Teff and FoxP3 Tregs at the invasive tumor margin of lymph
nodes, suggesting an immunomodulatory effect in HNSCC.
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Furthermore, a review of Lee et al. on Metformin, as a treatment
for endometrial cancer, presents the available clinical data and the
molecular mechanisms by which it exerts its effects, focusing on
how it may modify the TME. The multiple effects of metformin
on the regulation of metabolism, as well as the changes produced
in intercellular communication, make it a promising drug for the
treatment of different types of cancer.
One of the important challenges in the treatment of
cancer is the persistence of drug-resistant cell populations.
Resistant subpopulations arise, among other factors, through
modifications in the TME. The accumulation of extracellular
fibrous proteins and the modification of the extracellular matrix
are associated with tumor progression. Joyce et al. have studied
how this TME affects the sensitivity of breast cancer cells
to chemotherapeutic treatment. The cultured breast carcinoma
cells showed a stromal-dependent response to Doxorubicin,
suggesting that the conditions of the tumor microenvironment
largely govern the response to drugs.
A study by Mojena et al. investigated the effect of
a series of compounds derived from benzylamine/2-
thiophenomethylamine (ethylamine) that showed antitumor
activity on different melanoma tumor cell lines. These
compounds develop a potent cytotoxic/antiproliferative activity
in cells in vitro and in animal models of melanoma tumors,
enhancing animal survival.
Rappaport and Waldman explore the cGMP signaling in the
intestinal epithelium and the mechanisms by which it opposes
intestinal injury. In colorectal tumors, the expression of the
endogenous ligand of Guanylate cyclase C (GUCY2C) is lost and
the reconstitution of GUCY2C signaling through the genetic or
oral replacement of the ligand opposes tumorigenesis in mice.
These results suggest that colorectal cancer may arise in a tumor
microenvironment with a functional inactivation of GUCY2C.
In recent years we have seen the progress of immunological
therapy against different types of cancers. A crucial aspect
for its development has been its ability to reverse the
immunosuppression induced by tumors. In this sense, the
catabolic enzyme of tryptophan indoleamine 2,3-dioxygenase-
1 (IDO1) has received great attention as a driver of tumor-
mediated suppression. It has been shown that IDO1 is
overexpressed in different human cancers and associated with an
unfavorable prognosis. Fox et al. review the action of an inhibitor
of IDO1, Indoximod, as a co-adjuvant of treatment in several
types of tumors.
In conclusion, the current collection gathers researchers
studying disparate fields of the cancer ecosystem to
better understand how to target it. One must consider
historically how only limited efforts have been devoted
to study cancer ecosystems, which provide additional
information to that obtained when one component is
studied in isolation. Tumor ecosystems share productivity
features and vulnerabilities not only with coral reefs but
also with swamps (36, 49) and future studies will need
to determine their similarities and differences with other
physiological and pathological ecosystems. The analysis
and understanding of natural ecosystems can facilitate
new ways of cancer treatment. It may be that, as in the
Indian proverb of blind men encountering different parts
of an elephant, specialized researchers have seen only
one aspect of tumor aggressiveness and determined its
mechanisms accordingly.
AUTHOR CONTRIBUTIONS
This invited editorial was conceived by UM-O and RB,
contributing equally to the writing. MB provided information in
her areas of expertise.
FUNDING
This work was supported by National Institutes of Health Grants
NCI K08-CA175193 and NCI 5 P30 CA 56036 to UM-O and
by Instituto de Salud Carlos III—FIS [PI17/00412]—and Fondo
Europeo de Desarrollo Regional (FEDER) to RB.
REFERENCES
1. Paget S. The distribution of secondary growths in cancer of the breast. Cancer
Metastasis Rev. (1989) 8, 98–101.
2. Folkman J. Angiogenesis. Annu Rev Med. (2006) 57:1–18.
doi: 10.1146/annurev.med.57.121304.131306
3. McWilliam M, Chase TJ, Hoogenboom MO. Neighbor diversity regulates
the productivity of coral assemblages. Curr Biol. (2018) 28:3634–9.e3633.
doi: 10.1016/j.cub.2018.09.025
4. Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP.
Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. (2017)
14:113. doi: 10.1038/nrclinonc.2017.1
5. Rädecker N, Pogoreutz C, Voolstra CR, Wiedenmann J, Wild C. Nitrogen
cycling in corals: the key to understanding holobiont functioning? Trends
Microbiol. (2015) 23:490–7. doi: 10.1016/j.tim.2015.03.008
6. Wiebe WJ, Johannes RE, Webb KL. Nitrogen fixation in a coral reef
community. Science. (1975) 188:257–9. doi: 10.1126/science.188.4185.257
7. Ferrier-Pagès C, Godinot C, D’Angelo C, Wiedenmann J, Grover R.
Phosphorus metabolism of reef organisms with algal symbionts. Ecol
Monograph. (2016) 86:262–77. doi: 10.1002/ecm.1217
8. Comeau S, Edmunds PJ, Lantz CA, Carpenter RC. Water flow modulates the
response of coral reef communities to ocean acidification. Scient Rep. (2014)
4:6681. doi: 10.1038/srep06681
9. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz
AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer
associated fibroblasts and the tumor stroma. Cell Cycle. (2009) 8:3984–4001.
doi: 10.4161/cc.8.23.10238
10. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al.
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in
mice. J Clin Invest. (2008) 118:3930–42. doi: 10.1172/JCI36843
11. Garcia-Herrera N, Ferse SCA, Kunzmann A, Genin A. Mutualistic damselfish
induce higher photosynthetic rates in their host coral. J Exp Biol. (2017)
220:1803–11. doi: 10.1242/jeb.152462
12. Chase TJ, Pratchett MS, Frank GE, Hoogenboom MO. Coral-dwelling
fish moderate bleaching susceptibility of coral hosts. PLoS ONE. (2018)
13:e0208545. doi: 10.1371/journal.pone.0208545
13. De Goeij JM, VanOevelen D, VermeijMJA, Osinga R,Middelburg JJ, De Goeij
AFPM, et al. Surviving in a marine desert: the sponge loop retains resources
within coral reefs. Science. (2013) 342:108–10. doi: 10.1126/science.12
41981
Frontiers in Oncology | www.frontiersin.org 4 August 2019 | Volume 9 | Article 718
Martinez-Outschoorn et al. Editorial: Cancer Ecosystems
14. Morris LA, Voolstra CR, Quigley KM, Bourne DG, Bay LK. Nutrient
availability and metabolism affect the stability of coral–symbiodiniaceae
symbioses.TrendsMicrobiol. (2019) 27:678–89. doi: 10.1016/j.tim.2019.03.004
15. Barott KL, Venn AA, Perez SO, Tambutteeé S, Tresguerres M, Somero
GN. Coral host cells acidify symbiotic algal microenvironment to
promote photosynthesis. Proc Natl Acad Sci USA. (2015) 112:607–12.
doi: 10.1073/pnas.1413483112
16. Fuess LE, Mann WT, Jinks LR, Brinkhuis V, Mydlarz LD. Transcriptional
analyses provide new insight into the late-stage immune response of a diseased
caribbean coral. Roy Soc Open Sci. (2018) 5:172062. doi: 10.1098/rsos.172062
17. Libro S, Vollmer SV. Genetic signature of resistance to white band disease
in the caribbean staghorn coral acropora cervicornis. PLoS ONE. (2016)
11:e0146636. doi: 10.1371/journal.pone.0146636
18. Detournay O, Schnitzler CE, Poole A, Weis VM. Regulation of cnidarian-
dinoflagellate mutualisms: evidence that activation of a host TGFbeta innate
immune pathway promotes tolerance of the symbiont. Dev Comp Immunol.
(2012) 38:525–37. doi: 10.1016/j.dci.2012.08.008
19. Darwin C. The Structure and Distribution of Coral Reefs. 2nd ed. London:
Smith Elder and Co. (1974).
20. Hatcher BG. Coral reef primary productivity. A hierarchy
of pattern and process. Trends Ecol Evol. (1990) 5:149–55.
doi: 10.1016/0169-5347(90)90221-X
21. Warburg O. On the origin of cancer cells. Science. (1956) 123:309–14.
doi: 10.1126/science.123.3191.309
22. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg’s effect. J
Bioenerg Biomembr. (2007) 39:223–9. doi: 10.1007/s10863-007-9080-3
23. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of
cancer: metabolic reprogramming fuels cell growth and proliferation. Cell
Metab. (2008) 7:11–20. doi: 10.1016/j.cmet.2007.10.002
24. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim
H, et al. The bioenergetic signature of cancer: a marker of tumor progression.
Cancer Res. (2002) 62:6674–81.
25. Vander HeidenMG, Cantley LC, Thompson CB. Understanding theWarburg
effect: the metabolic requirements of cell proliferation. Science. (2009)
324:1029–33. doi: 10.1126/science.1160809
26. Tanner LB, Goglia AG,Wei MH, Sehgal T, Parsons LR, Park JO, et al. Four key
steps control glycolytic flux in mammalian cells. Cell Syst. (2018) 7:49–62 e48.
doi: 10.1016/j.cels.2018.06.003
27. Ko YH, Domingo-Vidal M, Roche M, Lin Z, Whitaker-Menezes D, Seifert
E, et al. TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR)
metabolically reprograms carcinoma and stromal cells in breast cancer. J Biol
Chem. (2016) 291:26291–303. doi: 10.1074/jbc.M116.740209
28. Gooptu M, Whitaker-Menezes D, Sprandio J, Domingo-Vidal M, Lin Z,
Uppal G, et al. Mitochondrial and glycolytic metabolic compartmentalization
in diffuse large B-cell lymphoma. Semin Oncol. (2017) 44:204–17.
doi: 10.1053/j.seminoncol.2017.10.002
29. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-
associated fibroblasts transfer energy and biomass to anabolic cancer
cells, fueling tumor growth. Semin Cancer Biol. (2014) 25:47–60.
doi: 10.1016/j.semcancer.2014.01.005
30. Reshef L, Koren O, Loya Y, Zilber-Rosenberg I, Rosenberg E. The
coral probiotic hypothesis. Environ Microbiol. (2006) 8:2068–73.
doi: 10.1111/j.1462-2920.2006.01148.x
31. Rosenberg E, Koren O, Reshef L, Efrony R, Zilber-Rosenberg I. The role of
microorganisms in coral health, disease and evolution. Nat Rev Microbiol.
(2007) 5:355–62. doi: 10.1038/nrmicro1635
32. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and
metastasis. Nat Med. (2013) 19:1423–37. doi: 10.1038/nm.3394
33. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a
glance. J Cell Sci. (2012) 125:5591–6. doi: 10.1242/jcs.116392
34. Lin S, Cheng S, Song B, Zhong X, Lin X, Li W, et al. The Symbiodinium
kawagutii genome illuminates dinoflagellate gene expression and coral
symbiosis. Science. (2015) 350:691–4. doi: 10.1126/science.aad0408
35. Duffy JE, Godwin CM, Cardinale BJ. Biodiversity effects in the wild are
common and as strong as key drivers of productivity.Nature. (2017) 549:261–
4. doi: 10.1038/nature23886
36. Hughes TP, Kerry JT, Álvarez-Noriega M, Álvarez-Romero JG, Anderson KD,
Baird AH, et al. Global warming and recurrent mass bleaching of corals.
Nature. (2017) 543:373–7. doi: 10.1038/nature21707
37. Mansfield KM, Carter NM, Nguyen L, Cleves PA, Alshanbayeva A, Williams
LM, et al. Transcription factor NF-κB is modulated by symbiotic status in
a sea anemone model of cnidarian bleaching. Scient Rep. (2017) 7:16025.
doi: 10.1038/s41598-017-16168-w
38. Vile D, Shipley B, Garnier E. Ecosystem productivity can be predicted from
potential relative growth rate and species abundance. Ecol Lett. (2006) 9:1061–
7. doi: 10.1111/j.1461-0248.2006.00958.x
39. Bellwood DR, Hughes TP, Hoey AS. Sleeping functional group drives coral-
reef recovery. Curr Biol. (2006) 16:2434–9. doi: 10.1016/j.cub.2006.10.030
40. Tilman D, Knops J, Wedin D, Reich P, Ritchie M, Siemann E. The influence of
functional diversity and composition on ecosystem processes. Science. (1997)
277:1300–2. doi: 10.1126/science.277.5330.1300
41. Cox E, Bonner J. Ecology. The advantages of togetherness. Science. (2001)
292:448–9. doi: 10.1126/science.1060456
42. Naeem S, Duffy JE, Zavaleta E. The functions of biological diversity in
an age of extinction. Science. (2012) 336:1401–6. doi: 10.1126/science.
1215855
43. Heemsbergen DA, Berg MP, Loreau M, van Hal JR, Faber JH, Verhoef
HA. Biodiversity effects on soil processes explained by interspecific
functional dissimilarity. Science. (2004) 306:1019–20. doi: 10.1126/science.11
01865
44. Cardinale BJ, Palmer MA, Collins SL. Species diversity enhances ecosystem
functioning through interspecific facilitation. Nature. (2002) 415:426–9.
doi: 10.1038/415426a
45. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev
Cancer. (2009) 9:239–52. doi: 10.1038/nrc2618
46. Rodriguez-Garcia A, Samso P, Fontova P, Simon-Molas H, Manzano A,
Castano E, et al. TGF-beta1 targets Smad, p38MAPK, and PI3K/Akt signaling
pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma
cells. FEBS J. (2017) 284:3437–54. doi: 10.1111/febs.14201
47. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong
SA, et al. Mitochondria primed by death signals determine cellular addiction
to antiapoptotic BCL-2 family members. Cancer Cell. (2006) 9:351–65.
doi: 10.1016/j.ccr.2006.03.027
48. Scott DW, Gascoyne RD. The tumour microenvironment in B cell
lymphomas. Nat Rev Cancer. (2014) 14:517–34. doi: 10.1038/nrc3774
49. Amend SR, Pienta KJ. Ecology meets cancer biology: the cancer swamp
promotes the lethal cancer phenotype. Oncotarget. (2015) 6:9669–78.
doi: 10.18632/oncotarget.3430
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Martinez-Outschoorn, Bartrons and Bartrons. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Oncology | www.frontiersin.org 5 August 2019 | Volume 9 | Article 718
